Gilead Sciences reports almost $900 mn in Q3 remdesivir sales
New York (AFP) - Remdesivir, a therapeutic to treat Covid-19, boosted third-quarter sales for pharmaceutical company Gilead Sciences by nearly $900 million, according to results released Wednesday by the drugmaker.The medication, sold under the brand name Veklury and originally developed to treat Ebola, has been shown to shorten the recovery time for patients hospitalized with the new coronavirus. Gilead reported a 17 percent jump in third-quarter revenues to $6.6 billion.The company reported a profit of $360 million, compared with a loss of $1.2 billion in the year-ago period.The US Food and ...